Literature DB >> 25249057

Cannabinoid modulation of functional connectivity within regions processing attentional salience.

Sagnik Bhattacharyya1, Irina Falkenberg2, Rocio Martin-Santos3, Zerrin Atakan1, Jose A Crippa4, Vincent Giampietro5, Mick Brammer5, Philip McGuire1.   

Abstract

There is now considerable evidence to support the hypothesis that psychotic symptoms are the result of abnormal salience attribution, and that the attribution of salience is largely mediated through the prefrontal cortex, the striatum, and the hippocampus. Although these areas show differential activation under the influence of delta-9-tetrahydrocannabinol (delta-9-THC) and cannabidiol (CBD), the two major derivatives of cannabis sativa, little is known about the effects of these cannabinoids on the functional connectivity between these regions. We investigated this in healthy occasional cannabis users by employing event-related functional magnetic resonance imaging (fMRI) following oral administration of delta-9-THC, CBD, or a placebo capsule. Employing a seed cluster-based functional connectivity analysis that involved using the average time series from each seed cluster for a whole-brain correlational analysis, we investigated the effect of drug condition on functional connectivity between the seed clusters and the rest of the brain during an oddball salience processing task. Relative to the placebo condition, delta-9-THC and CBD had opposite effects on the functional connectivity between the dorsal striatum, the prefrontal cortex, and the hippocampus. Delta-9-THC reduced fronto-striatal connectivity, which was related to its effect on task performance, whereas this connection was enhanced by CBD. Conversely, mediotemporal-prefrontal connectivity was enhanced by delta-9-THC and reduced by CBD. Our results suggest that the functional integration of brain regions involved in salience processing is differentially modulated by single doses of delta-9-THC and CBD and that this relates to the processing of salient stimuli.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25249057      PMCID: PMC4397391          DOI: 10.1038/npp.2014.258

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  54 in total

1.  Longitudinal topography and interdigitation of corticostriatal projections in the rhesus monkey.

Authors:  L D Selemon; P S Goldman-Rakic
Journal:  J Neurosci       Date:  1985-03       Impact factor: 6.167

2.  Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine.

Authors:  Giacomo Salvadore; Brian R Cornwell; Fabio Sambataro; David Latov; Veronica Colon-Rosario; Frederick Carver; Tom Holroyd; Nancy DiazGranados; Rodrigo Machado-Vieira; Christian Grillon; Wayne C Drevets; Carlos A Zarate
Journal:  Neuropsychopharmacology       Date:  2010-03-10       Impact factor: 7.853

3.  Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

Authors:  Deepak Cyril D'Souza; Walid Michel Abi-Saab; Steven Madonick; Kimberlee Forselius-Bielen; Anne Doersch; Gabriel Braley; Ralitza Gueorguieva; Thomas B Cooper; John Harrison Krystal
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

4.  From maps to mechanisms through neuroimaging of schizophrenia.

Authors:  Andreas Meyer-Lindenberg
Journal:  Nature       Date:  2010-11-11       Impact factor: 49.962

Review 5.  Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.

Authors:  Theresa H M Moore; Stanley Zammit; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis
Journal:  Lancet       Date:  2007-07-28       Impact factor: 79.321

6.  Characterization of effects of mean arterial blood pressure induced by cocaine and cocaine methiodide on BOLD signals in rat brain.

Authors:  Feng Luo; Gaohong Wu; Zhu Li; Shi-Jiang Li
Journal:  Magn Reson Med       Date:  2003-02       Impact factor: 4.668

7.  Temporal lobe dysfunction in medication-naïve boys with attention-deficit/hyperactivity disorder during attention allocation and its relation to response variability.

Authors:  Katya Rubia; Anna B Smith; Michael J Brammer; Eric Taylor
Journal:  Biol Psychiatry       Date:  2007-06-21       Impact factor: 13.382

Review 8.  Neurobiology of dopamine in schizophrenia.

Authors:  Olivier Guillin; Anissa Abi-Dargham; Marc Laruelle
Journal:  Int Rev Neurobiol       Date:  2007       Impact factor: 3.230

9.  Induction of psychosis by Δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing.

Authors:  Sagnik Bhattacharyya; José Alexandre Crippa; Paul Allen; Rocio Martin-Santos; Stefan Borgwardt; Paolo Fusar-Poli; Katya Rubia; Joseph Kambeitz; Colin O'Carroll; Marc L Seal; Vincent Giampietro; Michael Brammer; Antonio Waldo Zuardi; Zerrin Atakan; Philip K McGuire
Journal:  Arch Gen Psychiatry       Date:  2012-01

10.  Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study.

Authors:  Rebecca Kuepper; Jim van Os; Roselind Lieb; Hans-Ulrich Wittchen; Michael Höfler; Cécile Henquet
Journal:  BMJ       Date:  2011-03-01
View more
  42 in total

Review 1.  Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks.

Authors:  Mason M Silveira; Jonathon C Arnold; Steven R Laviolette; Cecilia J Hillard; Marta Celorrio; María S Aymerich; Wendy K Adams
Journal:  Neurosci Biobehav Rev       Date:  2016-09-14       Impact factor: 8.989

Review 2.  The why behind the high: determinants of neurocognition during acute cannabis exposure.

Authors:  Johannes G Ramaekers; Natasha L Mason; Lilian Kloft; Eef L Theunissen
Journal:  Nat Rev Neurosci       Date:  2021-05-27       Impact factor: 34.870

3.  Adverse Effects of Cannabis on Adolescent Brain Development: A Longitudinal Study.

Authors:  Jazmin Camchong; Kelvin O Lim; Sanjiv Kumra
Journal:  Cereb Cortex       Date:  2017-03-01       Impact factor: 5.357

4.  Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1-2 Phosphorylation.

Authors:  Roger Hudson; Justine Renard; Christopher Norris; Walter J Rushlow; Steven R Laviolette
Journal:  J Neurosci       Date:  2019-09-30       Impact factor: 6.167

Review 5.  Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol.

Authors:  Douglas L Boggs; Jacques D Nguyen; Daralyn Morgenson; Michael A Taffe; Mohini Ranganathan
Journal:  Neuropsychopharmacology       Date:  2017-09-06       Impact factor: 7.853

6.  Measuring Disturbance of the Endocannabinoid System in Psychosis: A Systematic Review and Meta-analysis.

Authors:  Amedeo Minichino; Morwenna Senior; Natascia Brondino; Sam H Zhang; Beata R Godwlewska; Philip W J Burnet; Andrea Cipriani; Belinda R Lennox
Journal:  JAMA Psychiatry       Date:  2019-09-01       Impact factor: 21.596

Review 7.  Phytocannabinoids modulate emotional memory processing through interactions with the ventral hippocampus and mesolimbic dopamine system: implications for neuropsychiatric pathology.

Authors:  Roger Hudson; Walter Rushlow; Steven R Laviolette
Journal:  Psychopharmacology (Berl)       Date:  2017-10-24       Impact factor: 4.530

8.  Cannabis users exhibit increased cortical activation during resting state compared to non-users.

Authors:  Shikha Prashad; Elizabeth S Dedrick; Francesca M Filbey
Journal:  Neuroimage       Date:  2018-06-09       Impact factor: 6.556

Review 9.  The effects of cannabis use on salience attribution: a systematic review.

Authors:  Surapi Bhairavi Wijayendran; Aisling O'Neill; Sagnik Bhattacharyya
Journal:  Acta Neuropsychiatr       Date:  2016-11-21       Impact factor: 3.403

10.  Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial.

Authors:  Sagnik Bhattacharyya; Robin Wilson; Elizabeth Appiah-Kusi; Aisling O'Neill; Michael Brammer; Jesus Perez; Robin Murray; Paul Allen; Matthijs G Bossong; Philip McGuire
Journal:  JAMA Psychiatry       Date:  2018-11-01       Impact factor: 21.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.